AR010377A1 - Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos. - Google Patents

Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.

Info

Publication number
AR010377A1
AR010377A1 ARP970106075A ARP970106075A AR010377A1 AR 010377 A1 AR010377 A1 AR 010377A1 AR P970106075 A ARP970106075 A AR P970106075A AR P970106075 A ARP970106075 A AR P970106075A AR 010377 A1 AR010377 A1 AR 010377A1
Authority
AR
Argentina
Prior art keywords
compositions
procedure
preparation
independently represent
pharmaceutical compositions
Prior art date
Application number
ARP970106075A
Other languages
English (en)
Original Assignee
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd
Publication of AR010377A1 publication Critical patent/AR010377A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composicion farmacéutica para secar por congelacion que comprende un nucleotido análogo, por ejemplo, un compuesto de la formula I en la cual R1 yR2 representan independientemente hidrogeno o halogeno, R3 y R4 representan independientement efenilo, o alquilo C1-C6 optativamente sustituido por uno omás sustituyentes seleccionados entre OR5, alquiltio C1-C6, NR6R7, fenilo, COOR8 y halogeno, R5, R6, R7 y R8 representan independientemente hidrogeno oalquilo C1-C6, y X representa unaporcion ácida, o una sal farmacéuticamente aceptable de la misma; manitol y un aditivo modificador que es cloruro de sodioo un poliol, que es adecuada para secar por congelacion; procedimiento para su preparacion y uso de dicha composicion paraf abricar un medicamento para eltratamiento de un transtorno de agregacion de plaquetas.
ARP970106075A 1996-12-20 1997-12-19 Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos. AR010377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation

Publications (1)

Publication Number Publication Date
AR010377A1 true AR010377A1 (es) 2000-06-07

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970106075A AR010377A1 (es) 1996-12-20 1997-12-19 Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.

Country Status (36)

Country Link
US (1) US6114313A (es)
EP (1) EP1007094B1 (es)
JP (1) JP4488538B2 (es)
KR (1) KR100552880B1 (es)
CN (1) CN1121875C (es)
AR (1) AR010377A1 (es)
AT (1) ATE221787T1 (es)
AU (1) AU758857B2 (es)
BR (1) BR9713974B1 (es)
CA (1) CA2275153C (es)
CZ (1) CZ300635B6 (es)
DE (1) DE69714616T2 (es)
DK (1) DK1007094T3 (es)
EE (1) EE03857B1 (es)
ES (1) ES2182133T3 (es)
FR (1) FR15C0060I2 (es)
HK (1) HK1026366A1 (es)
HU (1) HU226616B1 (es)
ID (1) ID21635A (es)
IL (1) IL130449A0 (es)
IS (1) IS1897B (es)
MY (1) MY121982A (es)
NO (1) NO327142B1 (es)
NZ (1) NZ336027A (es)
PL (1) PL190493B1 (es)
PT (1) PT1007094E (es)
RU (1) RU2205012C2 (es)
SA (1) SA97180719B1 (es)
SE (1) SE9604795D0 (es)
SI (1) SI1007094T1 (es)
SK (1) SK283137B6 (es)
TR (1) TR199901412T2 (es)
TW (1) TW522015B (es)
UA (1) UA66779C2 (es)
WO (1) WO1998028009A1 (es)
ZA (1) ZA9711055B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) * 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
EP2672975B1 (en) 2011-02-09 2016-04-20 The Medicines Company Methods for treating pulmonary hypertension
ES2904256T3 (es) 2013-03-09 2022-04-04 Chiesi Farm Spa Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
CN107206014A (zh) 2015-01-14 2017-09-26 奇斯药制品公司 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
EP3641784A1 (en) 2017-06-23 2020-04-29 Chiesi Farmaceutici S.p.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (es) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Atp凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
WO1993011785A1 (en) * 1991-12-09 1993-06-24 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition

Also Published As

Publication number Publication date
FR15C0060I1 (es) 2015-10-23
CN1121875C (zh) 2003-09-24
IL130449A0 (en) 2000-06-01
PT1007094E (pt) 2002-12-31
NO327142B1 (no) 2009-05-04
EE9900260A (et) 2000-02-15
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08
ZA9711055B (en) 1998-07-08
EE03857B1 (et) 2002-10-15
CA2275153C (en) 2008-03-25
HUP0000572A3 (en) 2002-10-28
RU2205012C2 (ru) 2003-05-27
UA66779C2 (uk) 2004-06-15
TR199901412T2 (xx) 1999-08-23
NO993067L (no) 1999-08-09
CZ300635B6 (cs) 2009-07-08
HUP0000572A2 (hu) 2001-05-28
BR9713974B1 (pt) 2010-02-23
SI1007094T1 (en) 2003-02-28
IS1897B (is) 2003-10-20
TW522015B (en) 2003-03-01
IS5064A (is) 1999-06-03
ATE221787T1 (de) 2002-08-15
EP1007094B1 (en) 2002-08-07
FR15C0060I2 (fr) 2016-04-22
CZ220199A3 (cs) 1999-11-17
MY121982A (en) 2006-03-31
EP1007094A1 (en) 2000-06-14
AU5351598A (en) 1998-07-17
DE69714616D1 (de) 2002-09-12
CN1240362A (zh) 2000-01-05
JP2001507022A (ja) 2001-05-29
ES2182133T3 (es) 2003-03-01
WO1998028009A1 (en) 1998-07-02
KR20000069598A (ko) 2000-11-25
BR9713974A (pt) 2000-04-11
NZ336027A (en) 2001-03-30
SK283137B6 (sk) 2003-03-04
SE9604795D0 (sv) 1996-12-20
ID21635A (id) 1999-07-08
US6114313A (en) 2000-09-05
CA2275153A1 (en) 1998-07-02
HU226616B1 (en) 2009-04-28
JP4488538B2 (ja) 2010-06-23
PL334006A1 (en) 2000-01-31
SA97180719B1 (ar) 2006-05-13
AU758857B2 (en) 2003-04-03
PL190493B1 (pl) 2005-12-30
NO993067D0 (no) 1999-06-21
HK1026366A1 (en) 2000-12-15
DE69714616T2 (de) 2003-04-03
DK1007094T3 (da) 2002-10-28

Similar Documents

Publication Publication Date Title
AR010377A1 (es) Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.
CO5070677A1 (es) Composicion topica para aclarar o reducir la pigmentacion que contiene derivados de resorcinol
HUP0401307A2 (hu) 5-HT6 hatással rendelkező új indolszármazékok, eljárás az előállításukra, és ezeket tartalmazó gyógyszerkészítmények
RU2003134544A (ru) Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
CO5251381A1 (es) Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen
ES2123654T3 (es) Carbapenems que contienen un grupo fenilo substituido con carboxi, procesos para su preparacion, productos intermedios y uso como antibioticos.
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR088919A2 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y uso
DK0447285T3 (da) Nephtalenderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler indeholdende dem
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
AR039826A1 (es) Composiciones y metodo para el tratamiento de infeccion en ganado vacuno y porcino
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
CO4940486A1 (es) Composiciones anti-fungosas
DK0499521T3 (da) Hidtil ukendte N-myristoyltransferaseinhibitorer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
AR037940A1 (es) Compuestos antivirales de piridoquinoxalina
AR040274A1 (es) Derivados de 1-[(indol-3-il)carbonil]piperazina como agonistas de canabinoides en el tratamiento del dolor y composiciones farmaceuticas
BR9911300A (pt) Composto, composição farmacêutica, e, uso do composto
AR021826A1 (es) COMPUESTOS DE 2- FENILPIRAN-4-ONA, PROCESOS PARA PREPARARLOS, USO DE UN COMPUESTO INTERMEDIARIO EN DICHOS, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y USO DE DICHOS COMPUESTOS Y DICHA COMPOSICIoN PARA LA FABRICACIoN DE UN MEDICAMENTO
RU99115747A (ru) Фармацевтические композиции для сушки вымораживанием
AR033828A1 (es) Benzofenonas y sulfonas como inhibidores de la captacion de glicina y composicion farmaceutica
CO5190692A1 (es) Derivados de pirrolidin-2,3,4-trion-3-oxima sustituida, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento

Legal Events

Date Code Title Description
FG Grant, registration